Trials / Completed
CompletedNCT01820572
A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 446 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belatacept | |
| DRUG | Tacrolimus | |
| DRUG | Cyclosporine |
Timeline
- Start date
- 2013-03-27
- Primary completion
- 2019-10-24
- Completion
- 2019-10-24
- First posted
- 2013-03-29
- Last updated
- 2021-01-05
- Results posted
- 2021-01-05
Locations
117 sites across 10 countries: United States, Argentina, Austria, Colombia, France, Germany, Netherlands, Norway, Sweden, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01820572. Inclusion in this directory is not an endorsement.